Category: Cancer

  • Nimotuzumab

    Description

    This page contains brief details about the drug nimotuzumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Nimotuzumab consists of the active Nimotuzumab. It is a monoclonal antibody used in cancer treatment.  It has been approved for the treatment of head and neck cancer, as well as for certain types of brain cancer. This medication is typically used with other cancer treatments, such as chemotherapy and radiation therapy.

    There are no absolute contraindications to Nimotuzumab, but there are some precautions and potential contraindications to consider. For example, patients with a history of severe allergic reactions or hypersensitivity to it or its components should not receive the medication. Additionally, patients with certain medical conditions, such as severe liver or kidney disease, may need to be monitored closely or have their dosages adjusted.

    Mechanism of Action of Nimotuzumab

    Nimotuzumab is primarily focused on its ability to target and bind to the epidermal growth factor receptor (EGFR) found on many cancer cells. By doing so, it can block the growth and spread of cancer cells, ultimately leading to improved outcomes for cancer patients. One of the advantages of this medication is its targeted therapy approach, which allows it to target cancer cells while minimizing damage to healthy cells specifically. This can help to reduce side effects and improve the overall quality of life for cancer patients undergoing treatment.

    Uses of Nimotuzumab

    Nimotuzumab is used in the treatment of several types of cancer, including head and neck cancer and certain types of brain cancer, such as glioma and glioblastoma. It is often combined with other cancer treatments, such as chemotherapy and radiation therapy, to improve overall and disease-free outcomes.

    Nimotuzumab Dosage available

    Nimotuzumab is an injectable medication that a healthcare professional administers. It is typically given as an intravenous injection. The dose and frequency will depend on the type of cancer being treated, the patient’s overall health, and other medications the patient may be taking.  If you miss a dose, contact your healthcare provider as soon as possible. Your healthcare provider may recommend rescheduling your next dose or adjusting your dosing schedule. Do not double the dose to make a missed dose.

  • Pamidronate

    Description

    This page contains brief details about the drug pamidronate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Pamidronate consists of the active substance Pamidronate. It is a medication that belongs to a class of drugs called bisphosphonates. It is used to treat high calcium levels in the blood, a condition known as hypercalcemia, which can be caused by cancer or other medical conditions. This helps to increase bone density and reduce the risk of fractures in people with osteoporosis (bone weakening) or other bone conditions. It works by slowing down the breakdown of bone tissue, which helps reduce the amount of calcium released into the bloodstream. The dosage and frequency of administration will depend on the individual’s medical condition and other factors such as age, weight, and overall health.

    Pamidronate was first approved by the U.S. Food and Drug Administration (FDA) in 1991 for treating hypercalcemia of malignancy, a condition in which cancer cells release calcium into the bloodstream. Since then, pamidronate has also been approved for treating other conditions related to bone metabolisms, such as osteoporosis and Paget’s disease of bone.

    Mechanism of Action of Pamidronate

    Pamidronate belongs to a class of drugs called bisphosphonates, which inhibit the activity of osteoclasts. Osteoclasts are responsible for breaking down bone tissue, which releases calcium into the bloodstream. By inhibiting osteoclasts’ activity, it helps slow down the breakdown of bone tissue and reduce the amount of calcium released into the bloodstream.

    Uses of Pamidronate

    Pamidronate is a medication used to treat various bone-related conditions, including hypercalcemia, cancer-related bone diseases, osteoporosis, and Paget’s disease of bone. It is also used in treatment of breast cancer metastasis (spread) to bone and osteolytic lesion of multiple myeloma (a type of bone cancer).

  • Vincristine Sulphate

    Description

    This page contains brief details about the drug vincristine sulphate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Vincristine sulphate is a chemotherapy medication containing the active constituent vincristine sulphate. It belongs to a class of drugs called vinca alkaloids, which inhibit the growth of cancer cells. This medication treats blood, head, breast, neck, kidney, bone, or lung cancers. It treats rhabdomyosarcoma (cancer that affects muscle tissue) and neuroblastoma (cancer that develops from immature nerve cells). It may also treat multiple myeloma (cancer of plasma cells), thyroid cancer, and a blood disorder known as idiopathic thrombocytopenic purpura (ITP). Cancer is a disorder in which cells multiply uncontrolled and abnormally.

    Vincristine sulphate was first approved by the FDA in 1963 for treating acute lymphocytic leukemia (ALL). Since then, it has received additional approvals for treating other types of cancer. Like all chemotherapy drugs, it can cause side effects, such as nausea, vomiting, constipation, hair loss, and fatigue. Patients should discuss the potential benefits and risks of treatment with their doctor.

    Mechanism of Action of Vincristine Sulphate

    The therapeutic effect of vincristine sulphate inhibits the growth and spread of cancer cells. Vincristine sulphate disrupts the formation and function of microtubules, which are structures inside cells that help with cell division and movement. By interfering with microtubule function, this medication can prevent cancer cells from dividing and multiplying and can also cause them to die.

    Uses of Vincristine Sulphate

    Vincristine sulphate is used to treat various types of cancer, including blood cancers such as acute lymphocytic leukemia (ALL), head and neck cancers, breast cancer, kidney cancer, bone cancer, and lung cancer. It is also used to treat idiopathic thrombocytopenic purpura (a condition in which the immune system attacks and destroys platelets cells) and multiple myeloma (a type of blood cancer that affects plasma cells). In addition, this medication is used to treat rhabdomyosarcoma (cancer that forms in the body’s soft tissues) and neuroblastoma (cancer that develops in certain nerve cells). It may also be used to treat thyroid cancer.

    Vincristine Sulphate Dosage available

    A healthcare professional usually administers vincristine sulphate intravenous injection (IV) in a hospital or clinical setting. It should not be taken orally or applied topically to the skin. If you miss a dose, do not double the dose to make up for the missed one.

  • Carboplatin

    Description

    This page contains brief details about the drug carboplatin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    The U.S. FDA approved Carboplatin as an anticancer medication to treat certain types of lung and ovarian cancer on 07th April 2003.

    Mechanism of Action of Carboplatin

    Carboplatin is used alone or with other drugs to treat ovarian cancer. This medication helps in controlling the spread of cancer.

    Uses of Carboplatin

    Carboplatin acts as an alkylating agent. This medicine inhibits the synthesis of DNA, RNA, and proteins which causes programmed cell death by interrupting DNA replication.

    Carboplatin Dosage available

    Carboplatin is an intravenous infusion drug that is injected through the veins. Your physician will choose the dosage and administration frequency based on your medical condition because it differs for each person.

  • Trastuzumab

    Description

    This page contains brief details about the drug trastuzumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Trastuzumab is a monoclonal antibody that was approved for its medical use on 25th September 1998.

    Mechanism of Action of Trastuzumab

    Trastuzumab Injection is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a monoclonal antibody belonging to the class a HER2/neu receptor antagonists. HER2 or human epidermal growth factor receptor 2 is a protein present in high concentrations on the surface of cancer cells of the breast and gastric region. Trastuzumab Injection works by binding with these receptors, ultimately inhibiting the growth of cancer cells.

    Uses of Trastuzumab

    Trastuzumab Injection has been developed to treat solid tumors by injecting it as an intravenous infusion. Trastuzumab Injection has been approved to treat HER2 overexpressing breast cancer and stomach cancer (gastro-oesophageal Junction adenocarcinoma).

    Trastuzumab Dosage available

    Trastuzumab is available as multi dose vial injections in the doses 150 mg and 440 mg. It is intended for intravenous infusion only and not for IV push or bolus.

  • Leuprolide Acetate

    Description

    This page contains brief details about the drug leuprolide acetate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Leuprolide Acetate is a gonadotropin-releasing hormone (GnRH) agonist approved for its medical use on 9th April 1985.

    Mechanism of Action of Leuprolide Acetate

    Leuprolide Acetate Injection is a biological agent that acts as hormonal drug therapy in cancer treatment. It comes under the class of Gonadotropin-releasing hormone (GnRH) agonist. It stimulates the luteinizing hormone and follicle-stimulating hormone of the pituitary gland, resulting in high estrogen in females and high testosterone and dihydrotestosterone in males. With continuous use, the levels of these hormones fall, and the organs which depend on these hormones become inactive. It is often administered in combination with other medications to alleviate pain symptoms.

    Uses of Leuprolide Acetate

    Leuprolide Acetate Injection has been developed to treat solid tumors by injecting it directly into the bloodstream. Leuprolide Acetate Injection has been approved to treat several conditions such as prostate cancer, endometriosis, uterine fibroids and other hormonal conditions.

    Leuprolide Acetate Dosage available

    Leuprolide acetate Injection is available in different doses.  This injection will be mostly administered by your doctor or nurse on your arm, thigh or abdomen after preparation. The site of injecting this medicine will be changed regularly. Your healthcare provider will administer this medicine once in three months.

  • Olaparib

    Description

    This page contains brief details about the drug olaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Olaparib is an anticancer medicine referred to as the Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor. It was approved for its medical use on 19th December 2014.

    Mechanism of Action of Olaparib

    Olaparib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a PARP inhibitor. PARP enzymes facilitate multiple DNA repair pathways and these repair mechanisms lead to the development of cancer cells. These enzymes specifically target cells with mutations in BRCA genes. Olaparib works by inhibiting PARP enzymes blocks repair of single stranded DNA, and ultimately hinders the growth and development of cancer cells. Olaparib is prescribed alone or in combination with other anticancer drugs like bevacizumab.

    Uses of Olaparib

    Olaparib Tablet has been developed as a maintenance therapy to treat adult patients with cancer in the ovaries, fallopian tube, peritoneum, pancreas, prostate due to BRCA mutation and have completely or partially responded to platinum-based chemotherapy.

    Olaparib Dosage available

    The recommended dose of Olaparib Tablet is 300mg twice a day with or without food. Olaparib Tablet is available in the doses of 100mg and 150mg and the strength varies according to the patient’s health condition. In patients with kidney impairment, the recommended dose is 200mg twice a day.

  • Rucaparib

    Description

    This page contains brief details about the drug rucaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Rucaparib is an anticancer drug that belongs to the class of medications called PARP (poly ADP-ribose polymerase) inhibitors. FDA approved this medicine on December 19, 2016, to treat certain types of cancers.

    Mechanism of Action of Rucaparib

    Rucaparib is an inhibitor of poly Adenosine diphosphate-ribose polymerase enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. It blocks an enzyme that repairs damaged DNA in the cancer cells, resulting in their death.

    Uses of Rucaparib

    Rucaparib is an orally available prescription drug. It is used to help maintain the response to other treatments for certain types of ovarian cancer, fallopian tube (a tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has reoccurred in adults who have previously completely responded or partially responded to other chemotherapy treatments.

    It is also used to treat certain types of cancer in people with specific gene (BRCA) changes who have received treatment with at least two other chemotherapy treatments. It is also indicated as maintenance therapy immediately after chemotherapy which has caused the tumor to shrink.

    Rucaparib Dosage available

    It is an orally available antineoplastic drug. The medicine is available as 200mg, 250mg, and 300mg tablets. Your doctor will decide the dose and duration of Rucaparib based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with water.

  • Pegaspargase

    Description

    This page contains brief details about the drug pegaspargase, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Pegaspargase is a chemotherapy drug containing the active constituent pegaspargase. It is used to treat a type of blood cancer called Acute Lymphoblastic Leukemia (ALL).This is a white blood cell cancer in which the immature white cells start growing out of control, thus preventing the production of functional blood cells. Combined with other chemotherapy drugs, this medication can help increase the chances of remission and long-term survival for people with ALL.

    Pegaspargase received its initial FDA approval in 1994 for treating leukemia. Since then, it has also been approved for use in various other countries. This medication is a prescription medication and should only be used under the supervision of a healthcare provider. It is particularly effective in treating children with ALL, who have a higher rate of remission and overall survival when included in their treatment plan.

    Mechanism of Action of Pegaspargase

    Pegaspargase is an enzyme that breaks down the amino acid asparagine in the body. Cancer cells require asparagine to grow and divide and cannot produce their asparagine. By breaking down asparagine in the body, this medication can effectively “starve” cancer cells of this essential nutrient, slowing their growth and promoting cancer cell death. However, normal cells in the body can produce their asparagine and are not as affected by the enzyme as cancer cells. Therefore, this medicine selectively targets cancer cells while sparing healthy cells in the body to some extent.

    Uses of Pegaspargase

    Pegaspargase is an antineoplastic agent used to treat certain types of cancer, particularly acute lymphoblastic leukemia (ALL) and Non- Hodgkin’s lymphoma.

    Pegaspargase Dosage available

    Pegaspargase is an enzyme that breaks down the amino acid asparagine in the body. Cancer cells require asparagine to grow and divide and cannot produce their asparagine. By breaking down asparagine in the body, this medication can effectively “starve” cancer cells of this essential nutrient, slowing their growth and promoting cancer cell death. However, normal cells in the body can produce their asparagine and are not as affected by the enzyme as cancer cells. Therefore, this medicine selectively targets cancer cells while sparing healthy cells in the body to some extent.

  • Lenvatinib

    Description

    This page contains brief details about the drug lenvatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

    Date of Approval

    Lenvatinib is composed of the active ingredient Lenvatinib. It is a tyrosine kinase inhibitor indicated for progressive or advanced thyroid cancer when radioactive iodine therapy is not beneficial. It is also used to treat previously untreated liver cancer patients who are not eligible for surgical treatment. Patients who have had an allergic reaction to lenvatinib or any of its components should not take this medication. Patients should inform their dentist or oral surgeon that they are taking this medication, as it can impair wound healing and increase the risk of bleeding.

    Lenvatinib was first approved by the United States Food and Drug Administration (FDA) in February 2015 for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Since then, it has received additional approvals for other indications, including the treatment of hepatocellular carcinoma (liver cancer) and renal cell carcinoma (kidney cancer).

    Mechanism of Action of Lenvatinib

    Lenvatinib blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cells’ growth and multiplication.

    Uses of Lenvatinib

    Lenvatinib is a medication that is used to treat several types of cancer, including thyroid, liver, and kidney cancer. In patients with radioactive iodine-refractory differentiated thyroid cancer, it can be used to slow the progression of the disease and reduce tumor size. It is also approved for the treatment of unresectable hepatocellular carcinoma (HCC), which is the most common type of liver cancer.

    Lenvatinib Dosage available

    Lenvatinib is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up the second dose.